Next Article in Journal
The Role of Autophagy in Hepatocellular Carcinoma
Next Article in Special Issue
Immunoregulatory Cell Depletion Improves the Efficacy of Photodynamic Therapy-Generated Cancer Vaccines
Previous Article in Journal
Connexin 50 Expression in Ependymal Stem Progenitor Cells after Spinal Cord Injury Activation
Previous Article in Special Issue
Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer
Open AccessArticle

Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy—Long-Term Outcome of a Phase II Pilot Study

1
Department of Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner Hauptstrasse 48, 5020 Salzburg, Austria
2
Department of Internal Medicine I, St. Mary’s Hospital, Gallwitzallee 123-143, 12249 Berlin, Germany
3
Institute of Pathology, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
4
Institute of Physiology and Pathophysiology, Paracelsus Medical University, Strubergasse 22, 5020 Salzburg, Austria
5
Second Department of Surgery, University of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany
6
Department for General and Visceral Surgery, Städtisches Krankenhaus Dresden-Friedrichstadt, Friedrichstraße 41, 01067 Dresden, Germany
*
Author to whom correspondence should be addressed.
Preliminary results were presented in abstract form at the annual meeting of the International Liver Cancer Association (ILCA), Milan, Italy (4–6 September 2009).
Academic Editors: Michael R. Hamblin and Ying-ying Huang
Int. J. Mol. Sci. 2015, 16(11), 26619-26628; https://doi.org/10.3390/ijms161125978
Received: 31 July 2015 / Revised: 21 October 2015 / Accepted: 23 October 2015 / Published: 6 November 2015
(This article belongs to the Special Issue Advances in Photodynamic Therapy)
Hilar cholangiocarcinoma (CC) is non-resectable in the majority of patients often due to intrahepatic extension along bile duct branches/segments, and even after complete resection (R0) recurrence can be as high as 70%. Photodynamic therapy (PDT) is an established palliative local tumor ablative treatment for non-resectable hilar CC. We report the long-term outcome of curative resection (R0) performed after neoadjuvant PDT for downsizing of tumor margins in seven patients (median age 59 years) with initially non-resectable hilar CC. Photofrin® was injected intravenously 24–48 h before laser light irradiation of the tumor stenoses and the adjacent bile duct segments. Major resective surgery was done with curative intention six weeks after PDT. All seven patients had been curatively (R0) resected and there were no undue early or late complications for the neoadjuvant PDT and surgery. Six of seven patients died from tumor recurrence at a median of 3.2 years after resection, the five-year survival rate was 43%. These results are comparable with published data for patients resected R0 without pre-treatment, indicating that neoadjuvant PDT is feasible and could improve overall survival of patients considered non-curatively resectable because of initial tumor extension in bile duct branches/segments—however, this concept needs to be validated in a larger trial. View Full-Text
Keywords: bile duct cancer; PDT; sodium porfimer; neoadjuvant therapy bile duct cancer; PDT; sodium porfimer; neoadjuvant therapy
Show Figures

Figure 1

MDPI and ACS Style

Wagner, A.; Wiedmann, M.; Tannapfel, A.; Mayr, C.; Kiesslich, T.; Wolkersdörfer, G.W.; Berr, F.; Hauss, J.; Witzigmann, H. Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy—Long-Term Outcome of a Phase II Pilot Study. Int. J. Mol. Sci. 2015, 16, 26619-26628.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop